A Neoadjuvant Pharmacodynamic Study Of RO4929097 (RO) in Pancreas Cancer.
Phase of Trial: Phase I
Latest Information Update: 27 Sep 2013
At a glance
- Drugs RG 4733 (Primary)
- Indications Pancreatic cancer
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 10 Jun 2017 Biomarkers information updated
- 01 Jul 2013 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 14 Jan 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.